

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/828,211	04/09/2001	Hideshi Fujiwake	P107331-00009	3660	
23353	7590 02/04/2004		EXAM	INER	
RADER FISHMAN & GRAUER PLLC LION BUILDING			TUNG, JOYCE		
	TREET N.W., SUITE 50	vi	ART UNIT	PAPER NUMBER	
WASHINGTON, DC 20036			1637		
			DATE MAILED: 02/04/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/828,211	FUJIWAKE, HIDESHI				
Office Action Summary	Examiner	Art Unit				
	Joyce Tung	1637				
The MAILING DATE of this communica Period for Reply	tion appears on the cover sheet	with the correspondence address				
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICA - Extensions of time may be available under the provisions of 3 after SIX (6) MONTHS from the mailing date of this communic - If the period for reply specified above is less than thirty (30) da - If NO period for reply is specified above, the maximum statuto - Failure to reply within the set or extended period for reply will, - Any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b). Status	TION. 7 CFR 1.136(a). In no event, however, magation. ays, a reply within the statutory minimum of rry period will apply and will expire SIX (6) No by statute, cause the application to become	v a reply be timely filed thirty (30) days will be considered timely. MONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed of	on <u>14 October 2003</u> .					
2a)⊠ This action is FINAL . 2b)[This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) <u>1-6</u> is/are pending in the application 4a) Of the above claim(s) is/are very 5) Claim(s) is/are allowed. 6) Claim(s) <u>1-6</u> is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction	withdrawn from consideration.					
Application Papers						
9) The specification is objected to by the E	xaminer.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection	= ' '					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by	the Examiner. Note the attact	ned Office Action or form PTO-152.				
Priority under 35 U.S.C. §§ 119 and 120						
12) Acknowledgment is made of a claim for a) All b) Some * c) None of: 1. Certified copies of the priority docentified copies of the priority docentified copies of the priority docentified copies of the certified copies of the application from the International * See the attached detailed Office action for a since a specific reference was included in 37 CFR 1.78. a) The translation of the foreign languated acknowledgment is made of a claim for a reference was included in the first sentence.	cuments have been received. cuments have been received in the priority documents have be Bureau (PCT Rule 17.2(a)). For a list of the certified copies in the first sentence of the speciage provisional application has domestic priority under 35 U.S.	of Application No en received in this National Stage of received. C. § 119(e) (to a provisional application) fication or in an Application Data Sheet. been received. C. §§ 120 and/or 121 since a specific				
Attachment(s)	· .	•				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-3) Information Disclosure Statement(s) (PTO-1449) Paper 	.948) 5) Notice of	w Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)				

Application/Control Number: 09/828,211

Art Unit: 1637

DETAILED ACTION

Following the entry of the amendment filed 10/14/2003, the claims 1-6 are pending.

- 1. The rejection of claims 1-6 under 35 U.S.C. 112, second paragraph in section 5a of the Office action mailed 7/17/2003 is withdrawn.
- 2. The rejection of claim 6 under 35 U.S.C. 112, second paragraph in section 5b of the Office action mailed 7/17/2003 is withdrawn.
- 3. Claims 1-6 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Gjerde et al. (6,210,885, issued 4/3/2001).

Applicant's arguments filed 10/14/2003 have been fully considered but they are not persuasive. The response argues that Gjerde et al. fail to specifically teach the use of a plurality of differently label oligonucleotides of varying types to detect a plurality of mutations sites on a single nucleic acid fragment. Gjerde et al. do disclose a plurality of the dyes Cascade Blue, FAM, JOE, TAMRA, and ROX, BODIPY-TR-X that are uniquely detectable at different emission wavelengths. These dyes can be used in a PCR system. Four different primer sets are used to amplify four different regions of a template (See column 28, lines 27-34). Therefore, Gjerde et al. do teach the use of a plurality of differently label oligonucleotides of varying types to detect a plurality of mutations sites on a single nucleic acid fragment.

The response further argues that Gjerde et al. only teach the simultaneous monitoring of a plurality of DNA fragment. However, based upon the teachings of Gjerde et al. (See column 28, lines 27-34) addressed above, four different regions of the template are amplified simultaneously in same container using four differently labeled primer sets and the differently labeled primer sets are detectable. Thus, one of ordinary skill in the art at the time of the instant

Application/Control Number: 09/828,211

Art Unit: 1637

Page 3

invention would have been motivated to apply the method of Gjerde et al. to detect a plurality of mutation sites on a single nucleic acid fragment with a plurality of differently labeled oligonucleotides of varying types. Therefore, the rejection is maintained.

Summary

4. No claims are allowable

Conclusion

5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

ETHAN WHISENANT PRIMARY EXAMINER Art Unit: 1637

6. Any inquiries concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112. The examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-6:00 PM.

Any inquiries of a general nature or relating to the status of this application should be directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

7. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung 3.7 January 12, 2004

> ETHAN WHISENANT PRIMARY EXAMINER